Page last updated: 2024-08-24

sertraline and Ovarian Neoplasms

sertraline has been researched along with Ovarian Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bitcover, R; Drinberg, V; Peer, D; Rajchenbach, W	1
Ahmed, A; Armaiz-Pena, GN; Bender, D; Christensen, DK; DeGeest, K; Domann, F; Goodheart, MJ; Lutgendorf, SK; Matsuo, K; Mendez, L; Penedo, FJ; Ramirez, E; Shinn, E; Sood, AK; Thaker, PH; Zand, B; Zimmerman, B	1

Other Studies

2 other study(ies) available for sertraline and Ovarian Neoplasms

Article	Year
Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. Cancer letters, 2014, Nov-28, Volume: 354, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Nanomedicine; Ovarian Neoplasms; Polyethylene Glycols; Random Allocation; Sertraline; Xenograft Model Antitumor Assays	2014
SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget, 2016, May-31, Volume: 7, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents, Second-Generation; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chi-Square Distribution; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Mice, Nude; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Odds Ratio; Ovarian Neoplasms; Proportional Hazards Models; Receptor, Serotonin, 5-HT2A; Risk Assessment; Risk Factors; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Time Factors; Tumor Microenvironment; United States; Up-Regulation; Xenograft Model Antitumor Assays	2016

Article

Year

Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine.

Cancer letters, 2014, Nov-28, Volume: 354, Issue:2

Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Nanomedicine; Ovarian Neoplasms; Polyethylene Glycols; Random Allocation; Sertraline; Xenograft Model Antitumor Assays

2014

SSRI use and clinical outcomes in epithelial ovarian cancer.

Oncotarget, 2016, May-31, Volume: 7, Issue:22

Topics: Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents, Second-Generation; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chi-Square Distribution; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Mice, Nude; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Odds Ratio; Ovarian Neoplasms; Proportional Hazards Models; Receptor, Serotonin, 5-HT2A; Risk Assessment; Risk Factors; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Time Factors; Tumor Microenvironment; United States; Up-Regulation; Xenograft Model Antitumor Assays

2016